12,372 trials
Pancreas Adenocarcinoma
Primary: Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone — 16.20; 14.16 Months — p=0.039
Colorectal Neoplasms · Trifluridine and Tipiracil · Circulating Tumor DNA
Primary: Disease-free Survival 1 (DFS1) — 9.30; 5.55 Months
Cystic Fibrosis · Cystic Fibrosis-related Diabetes
Primary: Weight — -4.6 kilograms
Dry Eye Disease
Primary: Change From Baseline to Day 29 in Corneal Fluorescein Staining Score in the Study Eye — 2.19; 2.31 score on a scale — p=0.315
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Asthma
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 147; 301; 21; 38 Participants
Diabetes Mellitus, Type 2 · Chronic Kidney Disease
Primary: Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*) — 0.98; 1.00; 0.98; 0.99 Ratio of kidney oxygenation…
Smoking Cessation
Primary: Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 — 6.0; 14.8 percentage of participants — p=0.0008
Early Breast Cancer · Locally Advanced Breast Cancer · Inflammatory Breast Cancer
Primary: Cross-over Period: Percentage of Participants Who Preferred the Administration of PH FDC SC in the Home Setting Compared With the Hospital Setting in Question 1 of the…
Thrombotic Microangiopathy
Primary: Participants With Thrombotic Microangiopathy (TMA) Response — 7 Participants
Pompe Disease (Late-onset)
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study Drug — 80; 37…
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 2.86; 2.56 Months — p=0.0005
Lung Diseases, Interstitial
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52 — -165.77; -84.64; -98.59 Milliliters (mL) — p=<0.0001
Adult Growth Hormone Deficiency · Endocrine System Diseases · Hormone Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation — 48; 52; 45; 7 Participants
Schizophrenia
Primary: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 — -12.17; -21.91; -23.44; -21.93 units on a scale…